The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022

Breast Cancer Summary

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

Request for Sample Market Report @

Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

Reasons to buy market report

This report will allow you to –
– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
– Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
– Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
– Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.


The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.
– Which drugs are used as the standard treatment in each setting of the disease?
– What are the competitive advantages of the existing novel drugs?
– Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.
– Which molecular targets appear most frequently in the pipeline?
– There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
– Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.
– How do failure rates vary by stage of development, molecule type, and molecular target?
– How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Related Market Research Reports:

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Global Non-Small Cell Lung Cancer Therapeutics Market Research Report 2017

Global Breast Cancer Market Research Report 2017

About Aarkstore:

Aarkstore Enterprise is among global marketing research companies involved in selling market reports across different industries and countries. We help serve thousands of clients annually with syndicated, custom market research and consulting. Collaborating with renowned market research partners, we have continued to etch our presence as an established as channel sales partner of market research intelligence on various frontiers. Clients from all sectors, including public, private, and commercial are endowed with best data modelling and processing structures with custom reports.

For further details, please Contact Us


Tagged: , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: